This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information.
NICE Recommendation
Availability in Scotland
2021 ESC Heart Failure Guidelines
As of 19th June 2024, NICE recommends Vyndaqel (tafamidis) as an option for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults. Tafamidis is only recommended if the company provides it according to the commercial arrangement.1
This advice applies in England and Wales.
To view the advice in full, visit the NICE Website.
Access to Vyndaqel on the NHS in England
Initially Vyndaqel will be prescribed to eligible adult patients with ATTR-CM by the National Amyloidosis Centre (NAC). To learn more about how you can refer your patients for treatment consideration, download the materials below.
This referral guidance has been developed & funded by Pfizer and co-created with the National Amyloidosis Centre and offers helpful information on how to refer a suspected or confirmed case of ATTR-CM to the NAC. This will enable the NAC to organise further diagnostic follow-up for suspected cases and initiate VYNDAQEL for eligible adult patients with confirmed ATTR-CM.
This referral guidance has been developed & funded by Pfizer and co-created with the National Amyloidosis Centre and offers clinicians a downloadable template to complete with patient information if you have a suspected or confirmed case of ATTR-CM. Sending the completed template to the NAC will enable further diagnostic follow-up for suspected cases and initiation of VYNDAQEL for eligible adult patients with confirmed ATTR-CM.
NICE = National Institute of Health and Care Excellence ; NHS = National Health Service
References:
Scottish Medicines Consortium (SMC) Advice:1
Advice: Following a second resubmission assessed under the end of life and orphan medicine process - VYNDAQEL (tafamidis) is accepted for use within NHS Scotland.
Indication under review: for the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
To view the advice in full, visit the SMC Website
If you are a healthcare professional based in Scotland and would like to learn more about how to access VYNDAQEL, get in touch with Pfizer here.
References:
The European Society of Cardiology (ESC) is non profit organisation formed of healthcare professionals working in all different fields of cardiology.1
Adapted from McDonagh TA, et al. Eur Heart J. 2021
*Class of recommendation. Class I: conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.
†Level of evidence. Level of evidence B: recommendation based on evidence from a single randomised trial or non-randomised studies
CV= cardivascular ;ESC=European Society of Cardiology ;hTTR-CA=hereditary transthyretin amyloid cardiac amyloidosis ;NYHA=New York Heart Association ;wTTR-CA=wild-type transthyretin cardiac amyloidosis
References:Learn about the efficacy of VYNDAQEL in patients with ATTR-CM
Learn more about Vyndaqel
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.